Paxlovid, a novel therapeutic agent, represents a significant advancement in the battle against the SARS-CoV-2 virus. Comprising a synergistic combination of nirmatrelvir and ritonavir, Paxlovid exerts its antiviral prowess by inhibiting the viral main protease (Mpro), thereby thwarting viral replication. Its oral administration facilitates early intervention, a critical strategy to mitigate disease progression and avert severe outcomes such as hospitalization and mortality.
Eligibility criteria:
SARS-CoV-2 infection is verified through either PCR or Lateral flow test within the past 5 days.
Additionally, the following criteria must be met:
- The individual is symptomatic with COVID-19 and exhibits no signs of clinical recovery.
- The onset of COVID-19 symptoms occurred within the last 7 days.
- The person belongs to a ‘highest’ risk group
CDC and NIH recommend several antiviral medications used to treat mild to moderate COVID-19 in people who are at high risk.
Resources:
https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html
